GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eargo Inc (NAS:EAR) » Definitions » Net Cash per Share

Eargo (EAR) Net Cash per Share : $1.03 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Eargo Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Eargo's Net Cash per Share for the quarter that ended in Sep. 2023 was $1.03.

The historical rank and industry rank for Eargo's Net Cash per Share or its related term are showing as below:

EAR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.03   Med: 4.55   Max: 11.69
Current: 2.5

During the past 6 years, the highest Price-to-Net-Cash Ratio of Eargo was 11.69. The lowest was 2.03. And the median was 4.55.

EAR's Price-to-Net-Cash is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 7.11 vs EAR: 2.50

Eargo Net Cash per Share Historical Data

The historical data trend for Eargo's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eargo Net Cash per Share Chart

Eargo Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial -161.11 -226.40 90.71 9.95 3.38

Eargo Quarterly Data
Dec17 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.89 3.38 2.30 1.59 1.03

Competitive Comparison of Eargo's Net Cash per Share

For the Medical Devices subindustry, Eargo's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eargo's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eargo's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Eargo's Price-to-Net-Cash falls into.



Eargo Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Eargo's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(101.238-31.224-0)/20.727
=3.38

Eargo's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

Net Cash per Share (Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(46.023-24.624-0)/20.7624
=1.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eargo  (NAS:EAR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Eargo Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Eargo's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Eargo (EAR) Business Description

Traded in Other Exchanges
N/A
Address
2665 North First Street, Suite 300, San Jose, CA, USA, 95134
Eargo Inc is a medical device company, focused on improving the quality of life of people with hearing loss. The company offers hearing aids, professional support services, and other insurance-related services through a direct-to-consumer format with a personalized, consumer-centric approach. The product portfolio includes Eargo Neo HiFi, Eargo 5, Eargo 6, Eargo 7, and related accessories.
Executives
Mark Thorpe officer: Chief Accounting Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William Brownie officer: Chief Operating Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Adam Laponis officer: Chief Financial Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Christian Gormsen director, officer: President and CEO C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Trit Garg director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Afshin Justin Sabet-peyman director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Onkarr Narula director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Donald J Spence director C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Psc Echo Gp, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Psc Echo, Lp 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
David James Wu director 411 FIRST AVENUE SOUTH, SUITE 600, SEATTLE WA 98104
Nina Richardson director C/O SILICON LABORATORIES, 400 W CESAR CHAVEZ, AUSTIN TX 78701
Katie J Bayne director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Geoff Pardo director 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB